Estados Unidos · Bolsa y Finanzas · Morningstar

ME Therapeutics Extends Option Agreement for CD22 Nanobody Asset

Publicado por Morningstar · Estados Unidos hace 12 h

ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company working on novel cancer-fighting drugs in the…

Leer el artículo completo en Morningstar Inicie sesión para guardar

MediaNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.morningstar.com)

ME Therapeutics Extends Option Agreement for CD22 Nanobody Asset

También te puede interesar

Anthropic can’t reliably control its AI agents. It’s cutting off its internal evals from the live internet instead

An NYU professor says OpenAI's mass release of math papers wiped out early-career researchers' projects

Trump turns to Russia in bid to lower diesel prices, but analysts see minimal impact

Trump's diesel agreement with Putin accused of contradicting Russia sanctions law

Big Controversy Upends a Contest About Microscopic Videos

Why Record Crude Output Can’t Solve America’s Diesel Crisis

ME Therapeutics Extends Option Agreement for CD22 Nanobody Asset

Compartir

También te puede interesar

Anthropic can’t reliably control its AI agents. It’s cutting off its internal evals from the live internet instead

An NYU professor says OpenAI's mass release of math papers wiped out early-career researchers' projects

Trump turns to Russia in bid to lower diesel prices, but analysts see minimal impact

Trump's diesel agreement with Putin accused of contradicting Russia sanctions law

Big Controversy Upends a Contest About Microscopic Videos

Why Record Crude Output Can’t Solve America’s Diesel Crisis